Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | CTSG | P08311 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8416125 | 0.87 | ELANE (0.55) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL7932603 | 0.85 | ELANE (0.57) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL2435976 | 0.81 | ELANE (0.51) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL2257976 | 0.81 | ELANE (0.61) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL16714701 | 0.81 | ELANE (0.51) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL24126788 | 0.77 | ELANE (0.56) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL9634937 | 0.77 | ELANE (0.47) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL9824381 | 0.77 | ELANE (0.57) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL17725119 | 0.77 | ELANE (0.47) | ELANECTSGF2PLGCMA1 | |
| SCHEMBL20840861 | 0.77 | ELANE (0.47) | ELANECTSGF2PLGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932695-B2 | Modified antibodies and related compounds, compositions and methods of use | SENSEI BIOTHERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2014197871-A2 | ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197866-A1 | MODIFIED ANTIBODIES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932695-B2 | Modified antibodies and related compounds, compositions and methods of use | FCGR1A, FCGR3B, FCGRT | ELANE 1926/4885CTSG 1238/4885F2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.